Annual capacity: 144 million units of disposable gloves
Within the framework of the Project, it is planned to build a plant for the production of latex gloves with a capacity of 144 million units of products annually. The production will be localized in the Special Economic Zone "Park of Innovative Technologies" in the Almaty region. The land plot is 5 hectares, the area of production premises is 3,100 sq. m.
Dolce LLP is a Kazakhstani pharmaceutical company founded in 2003 and specializing in the production and wholesale and retail sales of medical products. The company has many years of experience in the sale of medical products to state medical institutions in the country. Since 2011, he has been a supplier of a Single distributor - SK-Pharmacy LLP.
- According to Fitch Solutions forecasts, the global production of medical gloves will reach $3.7 billion by 2026. The average annual growth rate of syringe production will be 7.8% for the period 2021-2026.
- Domestic demand in the country is covered by imported supplies of products. By the end of 2020, Kazakhstan imported medical gloves in the amount of 24.3 million pairs worth 2.1 million US dollars. The average annual growth rate of supplies of medical gloves to the country over the past 5 years was -9%.
- Export potential. Launching production on an industrial scale and obtaining relevant international certificates of conformity and quality make it possible to significantly expand the geography of the Company's sales, primarily by mastering the markets of the CIS countries.
- Developed infrastructure and communications. For uninterrupted operation, the industrial facility will be provided with water, electricity, and there is also a transport infrastructure: roads are connected to the territory of the FEZ.
- Availability of sales channels. The initiator concluded a long-term contract for the supply of medical products with SC Pharmacy LLP within the framework of the support program for domestic manufacturers for a period of 10 years.
The Project requires financing in the amount of 4,124 thousand US dollars, of which:
- 70% (2,887 thousand US dollars) - debt financing in the presence of collateral;
- from 30% (1,237 thousand US dollars) - Investor participation.